Exact Mass: 428.23832120000003
Exact Mass Matches: 428.23832120000003
Found 138 metabolites which its exact mass value is equals to given mass value 428.23832120000003
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Irbesartan
Irbesartan is an angiotensin receptor blocker (ARB) used mainly for the treatment of hypertension. It competes with angiotensin II for binding at the AT1 receptor subtype. Unlike ACE inhibitors, ARBs do not have the adverse effect of dry cough. The use of ARBs is pending revision due to findings from several clinical trials suggesting that this class of drugs may be associated with a small increased risk of cancer. C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09C - Angiotensin ii receptor blockers (arbs), plain > C09CA - Angiotensin ii receptor blockers (arbs), plain C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist D057911 - Angiotensin Receptor Antagonists > D047228 - Angiotensin II Type 1 Receptor Blockers COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents CONFIDENCE standard compound; EAWAG_UCHEM_ID 2774 Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Irbesartan (SR-47436) is an orally active Ang II type 1 (AT1) receptor blocker (ARB). Irbesartan can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan can be used for the research of high blood pressure, heart failure, and diabetic kidney disease[1].
Bedoradrine
Falipamil
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
Lotrafiban
3alpha-hydroxy-11-hydroxy-iso-iphionan-4-one-(alpha-xylopyranoside-2-O-acetate)|3alpha-hydroxy-11-hydroxy-iso-iphionan-4-one-
13,14-dihydroxy-15,16 dimethoxy-(-)-6alpha-hydroxy-5alpha,8alpha,9alpha,10alpha-cleroda-3-en-18-oic acid
3,4-dimethoxy-benzoic acid 11-oxo-dodecahydro-7,14-methano-dipyrido[1,2-a;1,2-e][1,5]diazocin-2-yl ester|Cineverin|Cineverin (13-Veratroyloxy-lupanin)
5beta,11-dihydroxy-iphionan-4-one-11-O-(alpha-xylopyranoside-2-O-acetate)|5beta,11-dihydroxy-iphionan-4-one-11-O-
4,5-dioxo-seco-gamma-eudesmol-(alpha-xylopyranoside-2-O-acetate)|4,5-dioxo-seco-gamma-eudesmol-
irbesartan
C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09C - Angiotensin ii receptor blockers (arbs), plain > C09CA - Angiotensin ii receptor blockers (arbs), plain C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist D057911 - Angiotensin Receptor Antagonists > D047228 - Angiotensin II Type 1 Receptor Blockers COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 1074 CONFIDENCE standard compound; INTERNAL_ID 2094 CONFIDENCE standard compound; INTERNAL_ID 8187 Irbesartan (SR-47436) is an orally active Ang II type 1 (AT1) receptor blocker (ARB). Irbesartan can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan can be used for the research of high blood pressure, heart failure, and diabetic kidney disease[1].
Irbesartan (Avapro)
Irbesartan. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=138402-11-6 (retrieved 2024-07-09) (CAS RN: 138402-11-6). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0). Irbesartan (SR-47436) is an orally active Ang II type 1 (AT1) receptor blocker (ARB). Irbesartan can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan can be used for the research of high blood pressure, heart failure, and diabetic kidney disease[1].
Ala Lys Asn Pro
C18H32N6O6 (428.23832120000003)
Ala Lys Pro Asn
C18H32N6O6 (428.23832120000003)
Ala Asn Lys Pro
C18H32N6O6 (428.23832120000003)
Ala Asn Pro Lys
C18H32N6O6 (428.23832120000003)
Ala Pro Lys Asn
C18H32N6O6 (428.23832120000003)
Ala Pro Asn Lys
C18H32N6O6 (428.23832120000003)
Gly Lys Pro Gln
C18H32N6O6 (428.23832120000003)
Gly Lys Gln Pro
C18H32N6O6 (428.23832120000003)
Gly Pro Lys Gln
C18H32N6O6 (428.23832120000003)
Gly Pro Gln Lys
C18H32N6O6 (428.23832120000003)
Gly Gln Lys Pro
C18H32N6O6 (428.23832120000003)
Gly Gln Pro Lys
C18H32N6O6 (428.23832120000003)
Lys Ala Asn Pro
C18H32N6O6 (428.23832120000003)
Lys Ala Pro Asn
C18H32N6O6 (428.23832120000003)
Lys Gly Pro Gln
C18H32N6O6 (428.23832120000003)
Lys Gly Gln Pro
C18H32N6O6 (428.23832120000003)
Lys Asn Ala Pro
C18H32N6O6 (428.23832120000003)
Lys Asn Pro Ala
C18H32N6O6 (428.23832120000003)
Lys Pro Ala Asn
C18H32N6O6 (428.23832120000003)
Lys Pro Gly Gln
C18H32N6O6 (428.23832120000003)
Lys Pro Asn Ala
C18H32N6O6 (428.23832120000003)
Lys Pro Gln Gly
C18H32N6O6 (428.23832120000003)
Lys Gln Gly Pro
C18H32N6O6 (428.23832120000003)
Lys Gln Pro Gly
C18H32N6O6 (428.23832120000003)
Asn Ala Lys Pro
C18H32N6O6 (428.23832120000003)
Asn Ala Pro Lys
C18H32N6O6 (428.23832120000003)
Asn Lys Ala Pro
C18H32N6O6 (428.23832120000003)
Asn Lys Pro Ala
C18H32N6O6 (428.23832120000003)
Asn Pro Ala Lys
C18H32N6O6 (428.23832120000003)
Asn Pro Lys Ala
C18H32N6O6 (428.23832120000003)
Pro Ala Lys Asn
C18H32N6O6 (428.23832120000003)
Pro Ala Asn Lys
C18H32N6O6 (428.23832120000003)
Pro Gly Lys Gln
C18H32N6O6 (428.23832120000003)
Pro Gly Gln Lys
C18H32N6O6 (428.23832120000003)
Pro Lys Ala Asn
C18H32N6O6 (428.23832120000003)
Pro Lys Gly Gln
C18H32N6O6 (428.23832120000003)
Pro Lys Asn Ala
C18H32N6O6 (428.23832120000003)
Pro Lys Gln Gly
C18H32N6O6 (428.23832120000003)
Pro Asn Ala Lys
C18H32N6O6 (428.23832120000003)
Pro Asn Lys Ala
C18H32N6O6 (428.23832120000003)
Pro Gln Gly Lys
C18H32N6O6 (428.23832120000003)
Pro Gln Lys Gly
C18H32N6O6 (428.23832120000003)
Gln Gly Lys Pro
C18H32N6O6 (428.23832120000003)
Gln Gly Pro Lys
C18H32N6O6 (428.23832120000003)
Gln Lys Gly Pro
C18H32N6O6 (428.23832120000003)
Gln Lys Pro Gly
C18H32N6O6 (428.23832120000003)
Gln Pro Gly Lys
C18H32N6O6 (428.23832120000003)
Gln Pro Lys Gly
C18H32N6O6 (428.23832120000003)
ZK118182 isopropyl ester
C23H37ClO5 (428.23293820000004)
Bedoradrine
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist
HEXOCYCLIUM METHYLSULFATE
C21H36N2O5S (428.23448060000004)
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent
(3R,4R,5S)-ethyl 4-acetamido-5-(diallylamino)-3-(pentan-3-yloxy)cyclohex-1-enecarboxylate
C22H37ClN2O4 (428.24417120000004)
2-Phenyl-1-[4-(2-piperidin-1-YL-ethoxy)-phenyl]-1,2,3,4-tetrahydro-isoquinolin-6-OL
C28H32N2O2 (428.24636519999996)
N~2~-[(Benzyloxy)carbonyl]-N-[(1S,2S)-2-hydroxy-1-(4-hydroxybenzyl)propyl]-L-leucinamide
3-[[cyclopentyl-[[1-(phenylmethyl)-5-tetrazolyl]methyl]amino]methyl]-8-methyl-1H-quinolin-2-one
N-[(1R,3S,4aR,9aS)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide
N-[(1R,3R,4aS,9aR)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide
N-[(1R,3R,4aR,9aS)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]cyclobutanecarboxamide
N-[(1S,3S,4aR,9aS)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide
N-[(1S,3R,4aR,9aS)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide
N-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(1-piperidinyl)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-cyclopropylacetamide
N-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(1-piperidinyl)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-cyclopropylacetamide
N-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(1-piperidinyl)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-cyclopropylacetamide
(1R)-1-(hydroxymethyl)-7-methoxy-2-(1-oxobutyl)-N-propan-2-yl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]carboxamide
N-[(1S,3S,4aS,9aR)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide
N-[(1S,3R,4aS,9aR)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide
N-[(1R,3S,4aS,9aR)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide
N-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(1-piperidinyl)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-cyclopropylacetamide
N-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(1-piperidinyl)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-cyclopropylacetamide
N-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(1-piperidinyl)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-cyclopropylacetamide
N-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(1-piperidinyl)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-cyclopropylacetamide
N-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(1-piperidinyl)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-cyclopropylacetamide
(1S)-1-(hydroxymethyl)-7-methoxy-2-(1-oxobutyl)-N-propan-2-yl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]carboxamide
(2s,3r,4s,5r)-4,5-dihydroxy-2-({2-[(1r,4r)-4-methyl-3-oxo-4-(4-oxopentyl)cyclohexyl]propan-2-yl}oxy)oxan-3-yl acetate
2-(3,4-dimethylpent-3-en-1-yl)-3-hydroxy-n-(2-hydroxy-5-oxocyclopent-1-en-1-yl)-2-(methoxymethyl)-3,4-dihydro-1h-quinoline-6-carboximidic acid
2-{[2-(3a-acetyl-3-hydroxy-7a-methyl-hexahydro-1h-inden-5-yl)propan-2-yl]oxy}-4,5-dihydroxyoxan-3-yl acetate
(1r,3s,4r,6s,7s,8s,9s,10r,13s,14s,16r)-4,6,7,9,14,16-hexahydroxy-5,5,9,14-tetramethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadecan-3-yl acetate
2-(2-hydroxy-1-methoxy-5,6-dimethylhept-5-en-2-yl)-n-(2-hydroxy-5-oxocyclopent-1-en-1-yl)-2,3-dihydro-1h-indole-5-carboximidic acid
(2s,3r,4s,5r)-2-({2-[(3r,3ar,5r,7as)-3a-acetyl-3-hydroxy-7a-methyl-hexahydro-1h-inden-5-yl]propan-2-yl}oxy)-4,5-dihydroxyoxan-3-yl acetate
4,5-dihydroxy-2-({2-[4-methyl-3-oxo-4-(4-oxopentyl)cyclohexyl]propan-2-yl}oxy)oxan-3-yl acetate
(1s,3r,4r,6r,7r,8s,9r,10r,13r,14r,16s)-4,6,7,9,14,16-hexahydroxy-5,5,9,14-tetramethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadecan-3-yl acetate
(1s,3r,4r,6r,7r,8s,9r,10r,13r,14r,16s)-3,4,6,7,9,14-hexahydroxy-5,5,9,14-tetramethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadecan-16-yl acetate
(1s,3r,4r,6r,7r,8s,9r,10r,13r,14r,16r)-4,6,7,9,14,16-hexahydroxy-5,5,9,14-tetramethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadecan-3-yl acetate
(1r,2s,3r,4r,6s,8s,9r,10r,13r,14r,16r)-2,4,6,9,14,16-hexahydroxy-5,5,9,14-tetramethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁸]hexadecan-3-yl acetate
(1r,3r,4r,10s,14r,15r,17r,18s)-18-[(acetyloxy)methyl]-17-hydroxy-3-(methoxycarbonyl)-14-methyl-12λ⁵-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icosa-7(20),12(19)-dien-12-ylium
[C25H34NO5]+ (428.24368540000006)